SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)

by on 19 de desembre de 2022 with No hi ha comentaris
  • Kopetz, S., Bekaii-Saab, T. S., Yoshino, T., Chung, C. H., Zhang, X., Tabernero, J. (2022). SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). Journal of Clinical Oncology, 40(16) (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *